Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases

Citation for published version:
Jochems, ACC, Blair, GW, Stringer, MS, Thripleton, MJ, Clancy, U, Chappell, FM, Brown, R, Jaime Garcia, D, Hamilton, OKL, Morgan, AG, Marshall, I, Hetherington, K, Wiseman, S, Macgillivray, T, Valdés-hernández, MC, Doubal, FN & Wardlaw, JM 2020, 'Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases', Stroke. https://doi.org/10.1161/STROKEAHA.120.029163

Digital Object Identifier (DOI):
10.1161/STROKEAHA.120.029163

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Stroke

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases

Angela C.C. Jochems, MSc; Gordon W. Blair, MBChB; Michael S. Stringer, PhD; Michael J. Thripplenton, PhD; Una Clancy, MB, BCh, BAO; Francesca M. Chappell, PhD; Rosalind Brown, PhD; Daniela Jaime Garcia, MSc; Olivia K.L. Hamilton, MSc; Alasdair G. Morgan, MSc; Ian Marshall, PhD; Kirstie Hetherington, BSc (Hons); Stewart Wiseman, PhD; Tom MacGillivray, PhD; Maria C. Valdés-Hernández, PhD; Fergus N. Doubal, PhD; Joanna M. Wardlaw, MD

Background and Purpose—Perivascular spaces (PVS) around venules may help drain interstitial fluid from the brain. We examined relationships between suspected venules and PVS visible on brain magnetic resonance imaging.

Methods—We developed a visual venular quantification method to examine the spatial relationship between venules and PVS. We recruited patients with lacunar stroke or minor nondisabling ischemic stroke and performed brain magnetic resonance imaging and retinal imaging. We quantified venules on gradient echo or susceptibility-weighted imaging and PVS on T2-weighted magnetic resonance imaging in the centrum semiovale and then determined overlap between venules and PVS. We assessed associations between venular count and patient demographic characteristics, vascular risk factors, small vessel disease features, retinal vessels, and venous sinus pulsatility.

Results—Among 67 patients (69% men, 69.0±9.8 years), only 4.6% (range, 0%–18%) of venules overlapped with PVS. Total venular count increased with total centrum semiovale PVS count in 55 patients after accounting for venule-PVS overlap (β=0.468 [95% CI, 0.187–0.750]) and transverse sinus pulsatility (β=0.547 [95% CI, 0.309–0.786]) and adjusting for age, sex, and systolic blood pressure.

Conclusions—Despite increases in both visible PVS and suspected venules, we found minimal spatial overlap between them in patients with sporadic small vessel disease, suggesting that most magnetic resonance imaging-visible centrum semiovale PVS are per arteriolar rather than perivenular. (Stroke. 2020;51:00-00. DOI: 10.1161/STROKEAHA.120.029163.)

Key Words: brain ▪ humans ▪ risk factors ▪ small vessel disease ▪ venules ▪ venular insufficiency, systemic

Perivascular spaces (PVS) are fluid-filled spaces surrounding small perforating brain blood vessels. They may be part of the glymphatic system and be important for brain fluid drainage. When enlarged, PVS are visible on T2-weighted and T1-weighted magnetic resonance imaging (MRI) as round or linear hyperintensities/hypointensities respectively, primarily in the basal ganglia and centrum semiovale (CSO). They are neuroimaging features of small vessel disease (SVD). The glymphatic system concept is mostly based on rodent studies: drainage routes, flow mechanisms, and direction of fluid movement are unclear. Deoxygenated venous blood provides intrinsic contrast on gradient echo and susceptibility-weighted imaging sequences; therefore, vessels visible on these sequences are suspected to be venular. Several visual and computational venular quantification methods have been described (Table IV in the Data Supplement).

We examined spatial relationships between suspected venules and PVS and determined associations between venules and patient demographics, risk factors, SVD features, cerebral microvessel dysfunction, and retinal venules in patients with SVD.

Methods

We used data from 2 prospective studies of sporadic SVDs: iSVD study (Inflammation in SVD) and the MSS-3 (Mild Stroke Study 3). Both studies recruited patients with lacunar or minor nondisabling ischemic stroke (modified Rankin Scale score, <3) from NHS Lothian clinical stroke services and used similar 3T MRI sequences (Table V in the Data Supplement). MRI, demographic, and clinical data were obtained within 3 months after stroke. Patients gave written consent to participate in the study (Inflammation in SVD) or provided written informed consent (MSS-3) before participating. The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.120.029163. DOI: 10.1161/STROKEAHA.120.029163
informed consent. The studies were approved by the South East Scotland Research Ethics Committee (references 14/SS/1081 and 18/SS/0044). Data are accessible from the corresponding author.

MSS-3 performs phase-contrast MRI to measure pulsatility in the superior sagittal sinus, straight sinus, and transverse sinuses and calculates the pulsatility index as $\frac{\text{Flow}_{\text{maximum}} - \text{Flow}_{\text{minimum}}}{\text{Flow}_{\text{mean}}}$.

To quantify suspected venules, we obtained a total venular count in a region of interest in periventricular CSO on gradient echo/susceptibility-weighted imaging. The mean difference in venule-PVS overlap between 2 observers was zero (95% CI, −1 to 1) in interobserver reliability analysis (Data Supplement). One observer performed a total CSO PVS count on T2-weighted images in the venular region of interest. We compared gradient echo/susceptibility-weighted imaging with T2-weighted images to determine definite, probable, or possible overlap of venules and PVS, from their location, shape, and direction (Figure; detailed Methods in the Data Supplement).

On retinal images, we measured arteriolar and venular widths (central retinal arteriolar equivalent and central retinal venular equivalent, respectively) and arteriole-to-venule ratio.

We quantified SVD lesions using Fazekas scale for periventricular and deep white matter hyperintensities (WMH) and 5-point scale for PVS (for MRI, retinal imaging, processing, and analyses, see the Data Supplement).

We performed statistical analyses using IBM SPSS, version 24.0 (IBM Corp, Armonk, NY). We used both studies to develop the visual quantification method and assess the venule-PVS spatial relationship (details in the Data Supplement). In MSS-3, we additionally analyzed venular count versus patient demographics, vascular risk factors, SVD features, retinal vessels, and venous sinus pulsatility using multivariable linear regression adjusted for age, sex, and systolic blood pressure. We assessed assumptions of normality with standard methods: no assumptions appeared to be violated. In secondary multivariable analyses, we explored associations between significant predictors from the first analyses in addition to age, sex, and systolic blood pressure. Analyses were exploratory, so no formal correction for multiple comparisons was done.

**Results**

We included 67 patients (Table 1). Venules were most visible near the ventricles, whereas PVS were most visible adjacent to cortex (Figure [B and C]). When many PVS were present, more PVS were visible near the ventricular outer surface. Even when PVS overlapped with venules, PVS shapes often differed from the venule (Figures IV and V in the Data Supplement).

Per participant, the mean venular count was 33.22±11.83, mean PVS count was 55.33±28.62, and the median number of venule-PVS overlap was 1 (range, 0–8): only 81 venules had overlapping PVS in all 67 patients (mean percent of total venules that overlapped with PVS, 4.6%; range, 0%–18%; Figure VI in the Data Supplement).

Venular count increased with CSO PVS score ($\beta=0.331$ [95% CI, 0.058–0.604]), total CSO PVS count ($\beta=0.605$ [95% CI, 0.376–0.835]), and venule-PVS overlap ($\beta=0.500$ [95% CI, 0.256–0.744]). Lower venular count was associated with increased pulsatility in the sagittal ($\beta=-0.425$ [95% CI, −0.754 to −0.096]) and transverse ($\beta=-0.406$ [95% CI, −0.712 to −0.100]) sinuses (Table 2). No other associations were found (Tables VI and VII in the Data Supplement).

On substituting total CSO PVS count for PVS score in the model, venular count remained positively associated with PVS count ($\beta=0.468$ [95% CI, 0.187–0.750]) but not venule-PVS overlap. Venular count was still associated with total PVS count ($\beta=0.547$ [95% CI, 0.309–0.786]) in the model with transverse sinus pulsatility index.

**Discussion**

We found different locations and infrequent overlap between suspected venules and PVS on 3T MRI, suggesting that most venules and MRI-visible PVS are not spatially related. A 7T MRI study and a pathology study also found little venule-PVS overlap, suggesting that MRI-visible PVS in humans might be periarteriolar. As PVS increased, punctate PVS (possibly representing PVS around lenticulostriate arterioles from the basal ganglia) more often overlapped with PVS in the ventricular edge. Since venular count increased with total CSO PVS count, visible venules and PVS might both indicate worsening SVDs.

As this may be the first study of venular associations with demographics, risk factors, and MRI measurements, the analyses were exploratory. One study found associations between increased venule visibility and WMH volume, whereas another found the opposite. We did not find an...
arterial and venous sinus pulsatility. We found positive associations with retinal vessel widths. Retinal vessel density between venules and hypertension. We also found no associations between venular count and total CSO PVS count, suggesting that higher venular count might associate with increased pulsatility index but that higher venular count was associated with lower venous sinus pulsatility index. This might be indirectly explained by previous associations found between fewer visible venules and worse WMH and worse WMH with increased venous sinus pulsatility.14

Contrary to rodent studies, we did not find associations between fewer visible venules and worse WMH, perhaps due to the small sample. Our study is limited by the small sample and cross-sectional design. Artifacts like vessel calcification might be confused with venules. Strengths include developing an easy-to-apply venular quantification method for gradient echo and susceptibility-weighted imaging sequences. Future studies should examine longitudinal data from larger samples, assess changes over time and more associations.

Conclusions
Although we did not find a spatial relationship between suspected venules and PVS, more venules seemed to relate to enlarged PVS in the CSO. While we cannot exclude the presence of PVS around venules, enlarged PVS, as visible on MRI, might be more periarteriolar than perivenular.

Sources of Funding
This study was supported by the Fondation Leducq (16 CVD 05), Row Fogo Charitable Trust (BRO-D.FID3668413), UK Dementia Research Institute (Medical Research Council, Research Councils UK, Alzheimer’s Society, Alzheimer’s Research UK), Wellcome Trust–University of Edinburgh Institutional Strategic Support Fund, SINAPSE (Scottish Imaging Network: A Platform for Scientific Excellence; Scottish Funding Council, Chief Scientist Office), NHS Lothian Research and Development Office (Dr Thrippleton), Stroke Association Princess Margaret Research Development Fellowship (U. Clancy and G.W. Blair), Alzheimer Society (AS-PG-14-033), EU Horizon 2020 (666881, SVDs@Target; G.W. Blair), Garfield Weston Foundation–Stroke Association Senior Clinical Lectureship, NHS Research Scotland (Dr Doubal), Chief Scientist Office Scotland (U. Clancy), Siemens Healthineers (A.G. Morgan), and Alzheimer Nederland (A.C.C. Jochems).

Disclosures
A.G. Morgan receives funding from Siemens Healthineers. The other authors report no conflicts.

References
1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al; Standards for Reporting Vascular Changes on Neuroimaging (STRIVE

Table 1. Demographics

| Metric                        | iSVD Study (n=12) | MSS-3 (n=55) | Total (N=67) |
|-------------------------------|-------------------|--------------|--------------|
| Age, y                        | 74.00±6.59        | 67.97±10.06  | 69.04±9.77   |
| Men                           | 8 (66.7)          | 38 (69.1)    | 46 (68.7)    |
| Days after stroke             | 48 (31–276)       | 63 (24–100)  | 61 (24–276)  |
| Lacunar subtype               | …                 | 33 (60.0)    | …            |
| Hypertension                  | 9 (75.0)          | 42 (76.4)    | 51 (76.1)    |
| Hyperlipidemia                | 7 (58.3)          | 41 (74.5)    | 48 (71.6)    |
| History of smoking            | 0 (0)             | 11 (20)      | 11 (24.5)    |
| Diabetes mellitus             | 2 (16.7)          | 14 (25.5)    | 16 (23.9)    |
| Vascular risk factors*        |                   |              |              |
| 0                             | 1 (8.3)           | 2 (3.6)      | 3 (4.5)      |
| 1                             | 5 (41.7)          | 14 (25.5)    | 19 (28.4)    |
| 2                             | 5 (41.7)          | 23 (41.8)    | 28 (41.8)    |
| 3                             | 1 (8.3)           | 16 (29.1)    | 17 (25.4)    |
| 4                             | 0 (0)             | 0 (0)        | 0 (0)        |
| Systolic blood pressure       | 156.42±20.17      | 149.73±21.62 | 150.93±21.37 |
| Diastolic blood pressure      | 84.67±8.85        | 82.42±12.32  | 82.82±11.74  |
| Salt use                      |                   |              |              |
| No                            | 4 (33.3)          | 10 (18.2)    | 14 (20.9)    |
| Yes                           | 8 (66.7)          | 45 (81.8)    | 53 (79.1)    |

Continuous variables: mean±SD. Categorical variables: median (range) or n (%). BG indicates basal ganglia; CSO, centrum semiovale; DWMH, deep white matter hyperintensity; iSVD, Inflammation in SVD; MSS-3, Mild Stroke Study 3; PI, pulsatility index; PVH, periventricular hyperintensity; and PVS, perivascular space.

*Vascular risk factors composite score: hypertension, hyperlipidemia, diabetes mellitus, smoking.

Table 2. Venular Count Association With Small Vessel Disease Features and Venous Sinus Pulsatility

| Metric                        | β      | 95% CI       |
|-------------------------------|--------|--------------|
| PVS BG                        | −0.168 | −0.113 to 0.449 |
| PVS CSO score                 | 0.331  | 0.058 to 0.604* |
| Total CSO PVS count           | 0.605  | 0.376 to 0.835* |
| Venule-PVS overlap            | 0.500  | 0.256 to 0.744* |
| PVH Fazekas                   | −0.062 | −0.347 to 0.224 |
| DWMH Fazekas                  | −0.116 | −0.397 to 0.165 |
| Total Fazekas                 | −0.095 | −0.379 to 0.189 |
| Superior sagittal sinus PI    | −0.425 | −0.754 to −0.096* |
| Transverse sinus PI           | −0.406 | −0.712 to −0.100* |
| Straight sinus PI             | −0.280 | −0.592 to 0.031 |

Multivariable linear regression (age, sex, and systolic blood pressure adjusted). BG indicates basal ganglia; CSO, centrum semiovale; DWMH, deep white matter hyperintensity; PI, pulsatility index; PVH, periventricular hyperintensity; and PVS, perivascular space.

*P<0.05.
1. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822–838. doi: 10.1016/S1474-4422(13)70124-8

2. Brown R, Benveniste H, Black SE, Charpak S, Dichgans M, Joutel A, et al. Understanding the role of the perivascular space in cerebral small vessel disease. *Cardiovasc Res*. 2018;114:1462–1473. doi: 10.1093/cvr/cvy113

3. Jochems ACC, Blair GW, Stringer MS, Thrippleton MJ, Clancy U, Chappell FM, et al. Methods to quantify and visualize venules using structural magnetic resonance imaging scans, 2000-2019 [dataset]. University of Edinburgh. Department of Neuroimaging Sciences. Centre for Clinical Brain Sciences. Date available: January 21, 2020. Edinburgh DataShare. doi: 10.7488/ds/2755. https://datashare.is.ed.ac.uk/handle/10283/3557.

4. Thrippleton MJ, Blair GW, Valdes-Hernandez MC, Glatz A, Semple SI, Douhal F, et al. MRI relaxometry for quantitative analysis of USPIO uptake in cerebral small vessel disease. *Int J Mol Sci*. 2019;20:776. doi: 10.3390/ijms20030776.

5. Shi Y, Thrippleton MJ, Blair GW, Dickie DA, Marshall I, Hamilton I, et al. Small vessel disease is associated with altered cerebrovascular pulsatility but not resting cerebral blood flow. *J Cereb Blood Flow Metab*. 2020;40:85–99. doi: 10.1177/0271678X18037596.

6. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. *AJR Am J Roentgenol*. 1987;149:351–356. doi: 10.2214/ajr.149.2.351

7. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. *Cerebrovasc Dis*. 2015;39:224–231. doi: 10.1159/000375153

8. Ballerini L, Lovreglio R, Hernández MdCV, Gonzalez-Castro V, Maniega SM, Pellegrini E, et al. Application of the ordered logit model to optimising Frangi filter parameters for segmentation of perivascular spaces. *Proc Comput Sci*. 2016;90:61–67.

9. Bouvy WH, Bissel GI, Kuijf HJ, Kappelle LJ, Luijten PR, Zwanenburg B. Visualization of perivascular spaces and perforating arteries with 7 T magnetic resonance imaging. *Invest Radiol*. 2014;49:307–313. doi: 10.1097/RLI.0000000000000227

10. Okuidera T, Huang YP, Fukusumi A, Nakamura Y, Hatazawa J, Uemura K. Micro-angiographical studies of the medullary venous system of the cerebral hemisphere. *Neuropathology*. 1999;19:93–111. doi: 10.1046/j.1440-1789.1999.00215.x

11. Yan S, Wan J, Zhang X, Tong L, Zhao S, Sun J, et al. Increased visibility of deep medullary veins in leukoaraiosis: a 3-T MRI study. *Front Aging Neurosci*. 2014;6:144. doi: 10.3389/fnagi.2014.00144

12. Zhou M, Mao L, Wang Y, Wang Q, Yang Z, Li S, et al. Morphologic changes of cerebral veins in hypertensive rats: venous collagenosis is associated with hypertension. *J Stroke Cerebrovasc Dis*. 2015;24:530–536. doi: 10.1016/j.jstrokecerebrovasdis.2014.09.038

13. Zhang R, Zhou Y, Yan S, Zhong G, Liu C, Jiaerken Y, et al. A brain region-based deep medullary veins visual score on susceptibility weighted imaging. *Front Aging Neurosci*. 2017;9:269. doi: 10.3389/fnagi.2017.00269

14. Blair GW, Thrippleton MJ, Shi Y, Hamilton I, Stringer M, Chappell F, et al. Intracranial functional haemodynamic relationships in patients with cerebral small vessel disease [published online March 11, 2019]. *bioRxiv*. doi: 10.1101/572818. https://www.biorxiv.org/content/10.1101/572818v1.